Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study
NCT ID: NCT02076061
Last Updated: 2022-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2014-02-28
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
NCT01780298
Biomarkers of Chronic Obstructive Pulmonary Disease
NCT04963023
A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
NCT01268072
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622
Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease
NCT02627872
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GOLD stage I
No interventions assigned to this group
GOLD Stage II
No interventions assigned to this group
GOLD Stage III
No interventions assigned to this group
GOLD Stage IV
No interventions assigned to this group
Smokers/ex-smokers w/o COPD
No interventions assigned to this group
non-Smokers w/o COPD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
35 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Örestadskliniken
OTHER
Lund University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Johan Malm
Professor, Clincal Chemistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johan Malm
Role: STUDY_CHAIR
Clincal Chemistry, Lund University
György Marko-Varga
Role: PRINCIPAL_INVESTIGATOR
Clinical Protein Science & Imaging, Lund University
Mikael Truedsson
Role: PRINCIPAL_INVESTIGATOR
Örestadskliniken Malmö
Elisabet Wieslander
Role: PRINCIPAL_INVESTIGATOR
Division of Oncology and Pathology, Lund University
Thomas E Fehniger
Role: PRINCIPAL_INVESTIGATOR
Clinical Protein Science & Imaging, Lund University
Magnus Dahlbäck
Role: PRINCIPAL_INVESTIGATOR
Clinical Protein Science & Imaging, Lund University
Roger Appelqvist
Role: PRINCIPAL_INVESTIGATOR
Clinical Protein Science & Imaging, Lund University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Örestadskliniken
Malmo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KOL 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.